Vir Biotechnology (VIR) announced that the research collaboration agreement established with GSK (GSK) in 2020 has been amended to reflect that Vir will continue its ongoing efforts to discover, develop and advance next-generation solutions for COVID-19 and other potential coronavirus outbreaks, independently or with other partners. Together, the companies will continue working to ensure ongoing access to sotrovimab for patients around the world, where authorized, and to develop new therapies for influenza and other respiratory diseases. In April 2020, GSK and Vir entered into a collaboration to research and develop solutions for coronaviruses, including SARS-CoV-2, the virus that causes COVID-19. The collaboration used Vir’s proprietary monoclonal antibody platform technology to accelerate existing and identify new anti-viral antibodies that could be developed as therapeutic or preventive options to help address the COVID-19 pandemic and future outbreaks. In 2021, the Companies expanded their collaboration to include the research and development of new therapies for influenza and other respiratory viruses. Under the terms of the new amended agreement, Vir retains the sole rights to continue advancing next-generation solutions arising from the collaborative coronavirus vaccine and antibody programs, subject to tiered low- to mid-single digit royalties to GSK. The companies continue to collaborate on sotrovimab and VIR-7832, as well as a portfolio of other respiratory disease programs.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on VIR:
- Vir Biotechnology Announces Amended Collaboration Agreement with GSK
- Vir Biotechnology upgraded to Equal Weight from Underweight at Morgan Stanley
- Vir Biotechnology announces retirement of CEO, Backer to succeed
- Vir Biotechnology Announces Retirement of CEO George Scangos, Ph.D.; Appoints Marianne De Backer, MSc, Ph.D., MBA, as Successor
- Vir Biotechnology Achieves Target Enrollment for Groundbreaking Phase 2 PENINSULA Trial Evaluating VIR-2482 for Prevention of Seasonal Influenza A